TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD

Taro Pharmaceutical Industries Ltd.

14 Hakitor Street
Haifa 2624761
972 4 847 5700

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees1,413

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael PerfettoGroup VP604.09kN/A1961
Mr. Ara AprahamianExec. Officer602kN/AN/A
Mr. Uday V. BaldotaCEO & DirectorN/AN/A1970
Mr. Mariano BalaguerVP, CFO & Chief Accounting OfficerN/AN/A1973
Mr. Jeff HolmExec. Director Sales and OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

Corporate Governance

Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.